Get notified of page updates

APC Inherited Mutations

Learn about the cancer risks and medical options for people with inherited APC mutations

Stay up to date on research and information

Sign Up for FORCE Newsletters
Glossary on
off

Information for People with Inherited APC Mutations

People with a mutation in the APC gene have an increased risk for cancer, particularly, colorectal cancer. The lifetime cancer risks and risk management recommendations depend on several factors, including the location and type of APC mutation. APC mutations and their related cancer risks are typically divided into 3 categories:

  • Familial adenomatous polyposis (FAP)
  • Attenuated FAP
  • APC variant I1307K

Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP)

FAP and AFAP are caused by mutations in the APC gene. These conditions are rare, occurring in about one in 10,000 people. People with FAP may develop hundreds to thousands of in their colon and rectum, often beginning in their teenage years or early adulthood. Attenuated FAP is a milder subset of FAP that tends to begin at a later age than FAP. People with AFAP may develop dozens rather than hundreds or thousands of colon and rectal . Risk management recommendations for people with FAP and AFAP begin at a young age and continue throughout their life.

APC variant I1307K

A variant in the APC gene, known as I1307K (or sometimes called c.3920T>A or p.Ile1307Lys) is common in people of Eastern European Jewish ethnicity; about 7 percent will have this variant. People who test positive for I1307K do not develop FAP. They do have a slightly increased risk for colorectal cancer beginning in adulthood and risk management recommendations include more frequent screenings beginning at a slightly younger age than people in the general population.

There may be other medical concerns for people with a APC mutation, including cancer risks for children beginning at a young age.

Each of these topics is outlined in more detail in the sections highlighted below. 

Community Stories

January 25, 2021

Hereditary Colorectal Cancer: My AFAP Story

by Dan Dry Dock Shockley I am 60 years old, retired from the Navy (a veteran of Operation Desert Storm, Enduring Freedom and Iraqi Freedom) and a 9-year hereditary colon cancer warrior. In May 2012, at the age of 51, my first colonoscopy revealed 100...

More Information on APC Mutations

Cancer Risks

Cancer risk estimates are updated based on the latest research. Read about the lifetime risk for different cancers in people with inherited APC mutations. 

More info

Risk Management Options

Read about the latest expert guidelines for cancer screening and prevention for people with an APC mutation. Learn about research studies enrolling high-risk patients.   

More info

Cancer Treatment Options

People with an APC mutation who have been diagnosed with cancer may qualify for specific treatments or clinical trials. 

More info

Other Considerations

Risk management recommendations with FAP and AFAP begin at a young age. Learn about other important considerations for people with inherited APC mutations. 

More info

Participate in Research

The studies below are enrolling people with APC mutations and FAP or AFAP. To search for more studies, visit our Search and Enroll Tool

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP)

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP)

Clinicaltrials.gov identifier:
NCT05552755

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will...

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or  AXIN1 Mutation

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

Clinicaltrials.gov identifier:
NCT06005974

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.

More Resources

View Our Expert Webinars

Webinar: Colorectal Cancer Screening and Prevention in High-Risk Individuals

Webinar: What's New in Colorectal Cancer Treatment?

Last updated February 25, 2024